Procurement | Teleflex

Reduced central line-associated bloodstream infection
(CLABSI) incidence may improve patient satisfaction
and your health system’s reputation

What's the CLABSI impact?

According to available literature, the use of ARROWg+ard Blue Plus™ Catheters could reduce infections from 4.91¹ to 0.652² per 1,000 catheter days.

This means that a hospital using 1.000 CVCs annually, each for an average of 7 days, would see a reduction of 30 CLABSI cases per year.

What's the economic impact?

Each CLABSI incidence costs a health system approx. €10.000.^3-5
Reductions in incidence can lead to significant savings.

Number of CLABSIs times the average cost to a healthcare system of a single CLABSI incident.^1-5

Access our easy-to-use tool to customize the estimated cost of infections in your hospital

The savings figures provided are for illustrative purposes only and should not be interpreted as exact or guaranteed savings.
Actual savings may vary based on individual organisational circumstances, usage, and other factors.

Would you like to download our informational material?

Download brochure

Contact us

First Name *

Last Name *

Title *

Email Address *

Institution *

Zip/Postal Code *

I’d like to talk to my local Teleflex Vascular representative about setting up a product demo or trial.

Teleflex is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. Please review the Teleflex Privacy Policy.

I consent to receiving emails related to Teleflex products and services.

I have read and understand Teleflex's privacy policy.*

References:

European Centre for Disease Prevention and Control. Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals. https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-point-prevalence-survey-acute-care-hospitals-2022-2023.pdf
T. E. Philbeck, A. Bardin and J. G. McDonald. Observational, retrospective real-world evidence study demonstrates safety, performance and usefulness of antimicrobial central venous catheters. Journal of International Medical Research 2024, Vol. 52(9) 1–7
Tarricone, R., Torbica, A., Franzetti, F. et al. Hospital costs of central lineassociated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Eff Resour Alloc 8, 8 (2010). https://doi.org/10.1186/1478-7547-8-8
Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registrybased estimates. J Hosp Infect. 2009 Jun;72(2):97-103. doi: 1016/j. jhin.2008.12.012. Epub 2009 Feb 25. PMID: 19246122.
Orsi GB, Di Stefano L, Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. Infect Control Hosp Epidemiol. 2002 Apr;23(4):190-7. doi: 10.1086/502034. PMID: 12002233.

Contraindications:

The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs.

Clinical assessment of the patient must be completed to ensure no contraindications exist. Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas:

Patients with known hypersensitivity to chlorhexidine
In presence of device-related infections
In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway

No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference each referenced product's full package insert.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, and Arrowg+ard Blue Plus are trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners. MCI-102066

Savings With Chlorhexidine

What is Chlorhexidine?

Reduced central line-associated bloodstream infection
(CLABSI) incidence may improve patient satisfaction
and your health system’s reputation

What's the CLABSI impact?

What's the economic impact?

Would you like to download our informational material?

Contact us

Savings With Chlorhexidine

What is Chlorhexidine?

Reduced central line-associated bloodstream infection (CLABSI) incidence may improve patient satisfaction and your health system’s reputation

What's the CLABSI impact?

What's the economic impact?

Would you like to download our informational material?

Contact us

Reduced central line-associated bloodstream infection
(CLABSI) incidence may improve patient satisfaction
and your health system’s reputation